CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of multiple myeloma.
  
  LEARNING OBJECTIVES

  • Appraise the scientific rationale for targeting B-cell maturation antigen (BCMA) in the care of patients with multiple myeloma (MM), and assess the similarities and differences between various approved and investigational strategies directed at BCMA.
  • Appreciate available data documenting the activity of chimeric antigen receptor (CAR) T-cell therapy targeting BCMA in MM, and use this knowledge to identify patients who may be appropriate for this approach within or outside of a protocol setting.
  • Develop an understanding of the mechanism of action of and pivotal clinical trial findings with the recently FDA-approved BCMA-targeted antibody-drug conjugate belantamab mafodotin to facilitate integration into MM management algorithms.
  • Evaluate the biologic rationale for and available efficacy findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and identify patients for whom a clinical trial of this novel strategy should be considered.
  • Recognize adverse events associated with approved and investigational anti-BCMA therapies for MM, and implement strategies to educate patients and manage complications.
  • Recall the designs of ongoing clinical trials evaluating novel CAR T-cell therapies, antibody-drug conjugates and bispecific antibodies as monotherapy or in combination with other systemic approaches for MM, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Jesús G Berdeja, MD
  Director of Multiple Myeloma Research
  Sarah Cannon Research Institute
  Tennessee Oncology
  Sarah Cannon Center for Blood Cancer
  Nashville, Tennessee
  
  Consulting Agreements: bluebird bio, Bristol-Myers Squibb Company, Celgene Corporation, CRISPR Therapeutics, Janssen Biotech Inc, Kite, A Gilead Company, Legend Biotech, Secura Bio, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Amgen Inc, Astex Pharmaceuticals, bluebird bio, Bristol-Myers Squibb Company, Celator Pharmaceuticals Inc, Celgene Corporation, Celularity, CRISPR Therapeutics, Curis Inc, EMD Serono Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Ichnos Sciences, Incyte Corporation, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kesios Therapeutics Ltd, Lilly, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Poseida Therapeutics, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc, Vivolux.
  
  Noopur Raje, MD
  Director, Center for Multiple Myeloma
  Massachusetts General Hospital Cancer Center
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committee: Amgen Inc, bluebird bio, Bristol-Myers Squibb Company, Caribou Biosciences Inc, GlaxoSmithKline, Immuneel Therapeutics, Janssen Biotech Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from GlaxoSmithKline and Pfizer Inc.
  
  Release date: March 2022
  Expiration date: March 2023